Govt Brings Pregabalin Under Stricter Schedule H1 Rules Amid Rising Misuse Among Youth

The drug works by affecting nerve signals in the brain and nervous system, helping reduce pain sensations and abnormal nerve activity.

In a significant move aimed at curbing the growing misuse and illegal sale of prescription medicines, the Union Ministry of Health and Family Welfare has brought the drug "Pregabalin" under the stricter regulatory framework of Schedule H1 of the Drugs Rules, 1945.

The decision was officially notified through Gazette Notification G.S.R. 377(E) dated May 13, 2026, and published in the Gazette of India Extraordinary on May 20, 2026.

The move comes after several States reported increasing cases of misuse and abuse of Pregabalin, particularly among young people, along with seizures of illegally stocked and unauthorisedly sold quantities of the drug in different parts of the country.

Why Pregabalin Is Commonly Prescribed

Pregabalin is a prescription medicine widely used for the treatment of several neurological and chronic pain-related conditions. Doctors commonly prescribe it for:

• Neuropathic pain

• Chronic nerve-related pain disorders

• Fibromyalgia

• Certain neurological conditions

• Anxiety-related disorders in some cases

• Epilepsy and seizure management as adjunct therapy

The drug works by affecting nerve signals in the brain and nervous system, helping reduce pain sensations and abnormal nerve activity.

However, health authorities have observed increasing misuse of the medicine due to its sedative, euphoric and dissociative effects when consumed without proper medical supervision or in excessive quantities.

Rising Concern Over Drug Abuse Among Youth

Officials stated that reports received from multiple States indicated that Pregabalin was increasingly being abused recreationally, especially among youth populations.

According to health authorities, the medicine has reportedly been misused for producing calming, intoxicating or mind-altering effects, leading to growing public health concerns.

Recent enforcement actions also uncovered instances of illegal storage, unauthorised retail sales and trafficking of Pregabalin outside regulated medical channels.

Experts warn that misuse of Pregabalin can lead to several health risks, including:

• Addiction and dependency

• Dizziness and impaired coordination

• Sedation and drowsiness

• Mental confusion

• Respiratory depression when combined with other substances

• Increased risk of overdose in severe cases

Medical professionals have increasingly expressed concern about the non-medical use of prescription drugs becoming a growing challenge in India, particularly among younger demographics.

Shift from Schedule H to Stricter Schedule H1

Before this notification, Pregabalin was regulated under Schedule H of the Drugs and Cosmetics Rules, 1945. With the latest amendment, the drug will now fall under Schedule H1, which imposes significantly stricter controls on its sale, storage and prescription monitoring.

Schedule H1 drugs are considered sensitive medicines with a higher potential for misuse or abuse and therefore require enhanced monitoring throughout the supply chain.

The Government stated that the revised classification is aimed at strengthening accountability and preventing unauthorised access to the medicine.

New Rules Under Schedule H1 Classification

Under the revised regulations, several strict compliance requirements will now apply to Pregabalin across the pharmaceutical supply chain.

Sale Only Against Valid Prescription

Pregabalin can now be sold strictly against a valid prescription issued by a Registered Medical Practitioner (RMP).

Retail pharmacies will not be allowed to dispense the medicine without proper medical authorization.

Mandatory Sales Record Maintenance

Retailers and pharmacists must maintain a separate register documenting:

• Details of prescriptions

• Name of prescribing doctor

• Quantity sold

• Patient-related sale information

This requirement is intended to improve prescription monitoring and traceability.

Special Warning Label on Packaging

Manufacturers will now be required to prominently display the official Schedule H1 warning on product packaging.

The warning states:

"It is dangerous to take this preparation except in accordance with medical advice."

and

"Not to be sold by retail without the prescription of a Registered Medical Practitioner."

The objective is to increase public awareness regarding the risks associated with unsupervised use of the medicine.

Strict Penal Action for Violations

The Government has warned that any violations or non-compliance with the new rules will attract penal action under the Drugs and Cosmetics Act, 1940 and related rules.

Action may be taken against manufacturers, distributors, wholesalers, retailers or pharmacists found violating the provisions.

Strengthening Accountability Across the Supply Chain

Health authorities stated that the new regulation is intended to improve oversight across the pharmaceutical supply chain and curb illegal trafficking and misuse of prescription drugs.

The Ministry said the move would help:

• Prevent unauthorised access to Pregabalin

• Strengthen prescription monitoring systems

• Improve accountability among pharmacies and distributors

• Reduce illegal stockpiling and trafficking

• Protect public health from substance abuse risks

Officials also advised all stakeholders in the pharmaceutical sector, including manufacturers, wholesalers, distributors, retailers and pharmacists, to ensure strict compliance with the notification.

Growing Focus on Prescription Drug Regulation in India

The inclusion of Pregabalin under Schedule H1 reflects a broader effort by Indian health authorities to strengthen regulation of prescription medicines with abuse potential.

Globally, several countries have already tightened controls over Pregabalin and similar neurological drugs due to rising cases of misuse, dependency and illegal consumption.

Experts say the growing availability of certain prescription medicines without proper medical supervision has emerged as a major public health challenge in many countries.

Public health specialists have called for stronger monitoring systems, awareness campaigns, digital prescription tracking and stricter enforcement against illegal medicine sales to address the issue effectively.

Balancing Medical Access and Public Safety

While authorities aim to prevent misuse, medical experts emphasize that Pregabalin remains an important therapeutic medicine for patients suffering from chronic pain and neurological disorders.

Doctors say the objective of stricter regulation is not to restrict legitimate medical use but to ensure that the medicine is consumed safely under professional supervision.

Healthcare professionals have urged patients not to panic, noting that genuine prescriptions from registered doctors will continue to allow access to the medication for approved medical conditions.

India Strengthening Public Health Safeguards

The Government's latest decision signals increasing attention toward safeguarding public health against the risks associated with prescription drug abuse.

As India's pharmaceutical market continues to expand rapidly, regulators are focusing more strongly on balancing medicine accessibility with responsible usage, monitoring and enforcement.

The stricter regulation of Pregabalin under Schedule H1 is expected to play an important role in reducing unauthorised circulation of the drug while strengthening prescription-based healthcare practices across the country.